Nutrition and schizophrenia: associations worthy of continued revaluation

References

• Charlson FJ, Baxter AJ, Dua T, Degenhardt L, Whiteford HA, Vos T. Excess mortality from mental, neurological and substance use disorders in the Global Burden of Disease Study 2010. Epidemiol Psychiatr Sci. 2014;24(2):121–40.
   PubMed Web of Science ®Google Scholar
• Rehm J, Shield KD. Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019;21(2):10.
   PubMed Web of Science ®Google Scholar
• Roffman JL, Petruzzi LJ, Tanner AS, Brown HE, Eryilmaz H, Ho NF, et al. Biochemical, physiological and clinical effects of l-methylfolate in schizophrenia: a randomized controlled trial. Mol Psychiatry. 2017;23(2):316–22.
   PubMed Web of Science ®Google Scholar
• Vigo D, Thornicroft G, Atun R. Estimating the true global burden of mental illness. The Lancet Psychiatry. 2016;3(2):171–8.
   PubMed Web of Science ®Google Scholar
• Onaolapo AY, Onaolapo OJ. Schizophrenia Aetiology and Drug Therapy: A Tale of Progressive Demystification and Strides in Management. Advances in Pharmacology and Pharmacy. 2018;6(2):19–42.
   Web of Science ®Google Scholar
• Bushe C, Haddad P, Peveler R, Pendlebury J. The role of lifestyle interventions and weight management in schizophrenia. J Psychopharmacol. 2005;19(6 Suppl):28–35.
   PubMedGoogle Scholar
• Olfson M, Druss BG, Marcus SC. Trends in Mental Health Care among Children and Adolescents. N Engl J Med. 2015;372(21):2029–38.
   PubMed Web of Science ®Google Scholar
• Mauri M, Castrogiovanni S, Simoncini M, Iovieno N, Miniati M, Rossi A, et al. Effects of an Educational Intervention on Weight Gain in Patients Treated With Antipsychotics. J Clin Psychopharmacol. 2006;26(5):462–6.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci. 2014;34(46):15490–6.
   PubMed Web of Science ®Google Scholar
• Foster JA, McVey Neufeld KA. Gut-brain axis: how the microbiome influences anxiety and depression. Trends Neurosci. 2013;36(5):305–12.
   PubMed Web of Science ®Google Scholar
• Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13(10):701–12.
   PubMed Web of Science ®Google Scholar
• Badawy AA. Tryptophan availability for kynurenine pathway metabolism across the life span: Control mechanisms and focus on aging, exercise, diet and nutritional supplements. Neuropharmacology. 2017;112(Pt B):248–63.
   PubMedGoogle Scholar
• Erny D, Hrabě de Angelis AL, Jaitin D, Wieghofer P, Staszewski O, David E, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci. 2015;18(7):965–77.
   PubMed Web of Science ®Google Scholar
• Hoban AE, Stilling RM, Ryan FJ, Shanahan F, Dinan TG, Claesson MJ, et al. Regulation of prefrontal cortex myelination by the microbiota. Transl Psychiatry. 2016;6(4):e774.
   PubMedGoogle Scholar
• Ogbonnaya ES, Clarke G, Shanahan F, Dinan TG, Cryan JF, O'Leary OF. Adult Hippocampal Neurogenesis Is Regulated by the Microbiome. Biol Psychiatry. 2015;78(4):e7–9.
   PubMed Web of Science ®Google Scholar
• Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. Neuropharmacology. 2017;112(Pt B):399–412.
   PubMedGoogle Scholar
• Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut. 2000;47(6):861–9.
   PubMed Web of Science ®Google Scholar
• Mayer EA. Psychological stress and colitis. Gut. 2000;46(5):595–6.
   PubMed Web of Science ®Google Scholar
• Firth J, Marx W, Dash S, Carney R, Teasdale SB, Solmi M, et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom Med. 2019;81(3):265–80.
   PubMed Web of Science ®Google Scholar
• Teasdale S, Mörkl S, Müller-Stierlin AS. Nutritional psychiatry in the treatment of psychotic disorders: Current hypotheses and research challenges. Brain Behav Immun Health. 2020;5:100070.
   PubMedGoogle Scholar
• Seeman MV. The gut microbiome and antipsychotic treatment response. Behav Brain Res. 2021;396:112886.
   PubMed Web of Science ®Google Scholar
• Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry. 2013;13:176.
   PubMed Web of Science ®Google Scholar
• Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res. 2013;47(2):197–207.
   PubMed Web of Science ®Google Scholar
• Heald A, Sein K, Anderson S, Pendlebury J, Guy M, Narayan V, et al. Diet, exercise and the metabolic syndrome in schizophrenia: A cross-sectional study. Schizophr Res. 2015;169(1-3):494–5.
   PubMed Web of Science ®Google Scholar
• Young SN. Clinical nutrition: 3. The fuzzy boundary between nutrition and psychopharmacology. (0820-3946 (Print)).
   Google Scholar
• Gründer G, Cumming P. The Dopamine Hypothesis of Schizophrenia: Current status. In: Abel T, Nickl-Jockschat T, editor. The Neurobiology of Schizophrenia. San Diego (CA): Elsevier, 2016; 2016. 33. p. 109–24.
   Google Scholar
• Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III–the final common pathway. Schizophr Bull. 2009;35(3):549–62.
   PubMed Web of Science ®Google Scholar
• Arroll MA, Wilder L, Neil J. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J. 2014;13:91.
   PubMed Web of Science ®Google Scholar
• Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29(3):697–701.
   PubMed Web of Science ®Google Scholar
• Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull. 2003;29(2):393–7.
   PubMed Web of Science ®Google Scholar
• Nunes D, Eskinazi B, Camboim Rockett F, Delgado VB, Schweigert Perry ID. Nutritional status, food intake and cardiovascular disease risk in individuals with schizophrenia in southern Brazil: a case-control study. Rev Psiquiatr Salud Ment. 2014;7(2):72–9.
   PubMed Web of Science ®Google Scholar
• Joseph J, Depp C, Shih PB, Cadenhead KS, Schmid-Schönbein G. Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia? Front Neurosci. 2017;11:155.
   PubMed Web of Science ®Google Scholar
• Stokes C, Peet M. Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms. Nutr Neurosci. 2004;7(4):247–9.
   PubMed Web of Science ®Google Scholar
• Sugawara N, Yasui-Furukori N, Sato Y, Saito M, Furukori H, Nakagami T, et al. Dietary patterns are associated with obesity in Japanese patients with schizophrenia. BMC Psychiatry. 2014;14:184.
   PubMed Web of Science ®Google Scholar
• Kapur S. Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia. Am J Psychiatry. 2003;160:13–23.
   PubMed Web of Science ®Google Scholar
• Elman I, Borsook D, Lukas SE. Food Intake and Reward Mechanisms in Patients with Schizophrenia: Implications for Metabolic Disturbances and Treatment with Second-Generation Antipsychotic Agents. Neuropsychopharmacology. 2006;31(10):2091–120.
   PubMed Web of Science ®Google Scholar
• Vucetic Z, Reyes TM. Central dopaminergic circuitry controlling food intake and reward: implications for the regulation of obesity. Wiley Interdiscip Rev Syst Biol Med. 2010;2(5):577–93.
   PubMed Web of Science ®Google Scholar
• Blum K, Liu Y, Shriner R, Gold MS. Reward circuitry dopaminergic activation regulates food and drug craving behavior. Curr Pharm Des. 2011;17(12):1158–67.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci. 2012;11:1–24.
   PubMedGoogle Scholar
• Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97–115.
   PubMed Web of Science ®Google Scholar
• Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25(4):455–67.
   PubMed Web of Science ®Google Scholar
• Erhardt S, Blennow K, Nordin C, Skogh E, Lindström LH, Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett. 2001;313(1-2):96–8.
   PubMed Web of Science ®Google Scholar
• Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 2010;36(2):211–8.
   PubMed Web of Science ®Google Scholar
• Stone TW, Stoy N, Darlington LG. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013;34(2):136–43.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011;70(7):663–71.
   PubMed Web of Science ®Google Scholar
• Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, et al. Cortisol and Inflammatory Biomarkers Predict Poor Treatment Response in First Episode Psychosis. Schizophr Bull. 2015;41(5):1162–70.
   PubMed Web of Science ®Google Scholar
• Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40(1):181–91.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51(3):199–214.
   PubMed Web of Science ®Google Scholar
• Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003;1003:318–27.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148(10):1301–8.
   PubMed Web of Science ®Google Scholar
• McWhinney SR, Brosch K, Calhoun VD, Crespo-Facorro B, Crossley NA, Dannlowski U, et al. Obesity and brain structure in schizophrenia - ENIGMA study in 3021 individuals. Mol Psychiatry. 2022;27(9):3731–7.
   PubMed Web of Science ®Google Scholar
• Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol. 2013;16(6):1205–18.
   PubMed Web of Science ®Google Scholar
• Mazereel V, Detraux J, Vancampfort D, van Winkel R, De Hert M. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness. Front Endocrinol (Lausanne. 2020;11:573479.
   PubMed Web of Science ®Google Scholar
• Vancampfort D, Wampers M, Mitchell AJ, Correll CU, De Herdt A, Probst M, et al. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls. World Psychiatry. 2013;12(3):240–50.
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Jama. 2009;302(16):1765–73.
   PubMed Web of Science ®Google Scholar
• Pérez-Iglesias R, Ortiz-Garcia de la Foz V, Martínez García O, Amado JA, Garcia-Unzueta MT, Ayesa-Arriola R, et al. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res. 2014;159(1):90–4.
   PubMed Web of Science ®Google Scholar
• Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;28(1):27–31.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry. 2003;48(10):689–94.
   PubMed Web of Science ®Google Scholar
• Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, et al. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry. 2019;19(1):114.
   PubMedGoogle Scholar
• Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring). 2010;18(8):1646–51.
   PubMed Web of Science ®Google Scholar
• Smith RC, Rachakonda S, Dwivedi S, Davis JM. Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. Psychiatry Res. 2012;199(3):159–63.
   PubMed Web of Science ®Google Scholar
• Ballon JS, Pajvani UB, Mayer LE, Freyberg Z, Freyberg R, Contreras I, et al. Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. J Psychopharmacol. 2018;32(5):533–40.
   PubMed Web of Science ®Google Scholar
• Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. Antipsychotic drug-induced weight gain mediated by histamine H 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104(9):3456–9.
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol Ther. 2010;125(1):169–79.
   PubMed Web of Science ®Google Scholar
• Erickson ZD, Kwan CL, Gelberg HA, Arnold IY, Chamberlin V, Rosen JA, et al. A Randomized, Controlled Multisite Study of Behavioral Interventions for Veterans with Mental Illness and Antipsychotic Medication-Associated Obesity. J Gen Intern Med. 2017;32(Suppl 1):32–9.
   PubMedGoogle Scholar
• Storch Jakobsen A, Speyer H, Nørgaard HCB, Hjorthøj C, Krogh J, Mors O, et al. Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders - Baseline and two-years findings from the CHANGE trial. Schizophr Res. 2018;199:96–102.
   PubMed Web of Science ®Google Scholar
• Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen HL, Rickels K. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes. 2013;62(9):3232–40.
   PubMed Web of Science ®Google Scholar
• Emsley R, Asmal L, Chiliza B, du Plessis S, Carr J, Kidd M, et al. Changes in brain regions associated with food-intake regulation, body mass and metabolic profiles during acute antipsychotic treatment in first-episode schizophrenia. Psychiatry Research: Neuroimaging. 2015;233(2):186–93.
   Web of Science ®Google Scholar
• Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. (0002-953X (Print)).
   Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology. 2007;192(3):441–8.
   PubMed Web of Science ®Google Scholar
• Smith RC, Maayan L, Wu R, Youssef M, Jing Z, Sershen H, et al. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study. Psychopharmacology (Berl). 2018;235(12):3545–58.
   PubMed Web of Science ®Google Scholar
• Correll CU, Newcomer JW, Silverman B, DiPetrillo L, Graham C, Jiang Y, et al. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Am J Psychiatry. 2020;177(12):1168–78.
   PubMed Web of Science ®Google Scholar
• Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. (0004-8674 (Print)).
   Google Scholar
• Usher K, Park T, Foster K, Buettner P. A randomized controlled trial undertaken to test a nurse-led weight management and exercise intervention designed for people with serious mental illness who take second generation antipsychotics. J Adv Nurs. 2013;69(7):1539–48.
   PubMed Web of Science ®Google Scholar
• Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, et al. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res. 2009;111(1-3):9–16.
   PubMed Web of Science ®Google Scholar
• Milano W, Grillo F, Del Mastro A, De Rosa M, Sanseverino B, Petrella C, et al. Appropriate intervention strategies for weight gain induced by olanzapine: a randomized controlled study. Adv Ther. 2007;24(1):123–34.
   PubMed Web of Science ®Google Scholar
• Do KQ BP, Cabungcal JH, Conus P, Gysin R, et al. Behavioral Neurochemistry, Neuroendocrinology and Molecular Neurobiology. In: Lajtha A, editor. Handbook of Neurochemistry and Molecular Neurobiology. New York: Springer; 2009.
   Google Scholar
• Do KQ, Cabungcal JH, Frank A, Steullet P, Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. (1873-6882 (Electronic)).
   Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine – a safe antidote for cysteine/glutathione deficiency. (1471-4892 (Print)).
   Google Scholar
• Mullier E, Roine T, Griffa A, Xin L, Baumann PS, Klauser P, et al. N-Acetyl-Cysteine Supplementation Improves Functional Connectivity Within the Cingulate Cortex in Early Psychosis: A Pilot Study. Int J Neuropsychopharmacol. 2019;22(8):478–87.
   PubMed Web of Science ®Google Scholar
• Klauser P, Xin L, Fournier M, Griffa A, Cleusix M, Jenni R, et al. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. Transl Psychiatry. 2018;8(1):220.
   PubMedGoogle Scholar
• Retsa C, Knebel JF, Geiser E, Ferrari C, Jenni R, Fournier M, et al. Treatment in early psychosis with N-acetyl-cysteine for 6months improves low-level auditory processing: Pilot study. Schizophr Res. 2018;191:80–6.
   PubMed Web of Science ®Google Scholar
• McQueen G, Lay A, Lally J, Gabay AS, Collier T, Lythgoe DJ, et al. Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia. Psychopharmacology (Berl). 2020;237(2):443–51.
   PubMed Web of Science ®Google Scholar
• Yang YS, Davis MC, Wynn JK, Hellemann G, Green MF, Marder SR. N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study. Schizophr Res. 2019;208:479–80.
   PubMed Web of Science ®Google Scholar
• Carmeli C, Knyazeva MG, Cuénod M, Do KQ. Glutathione precursor N-acetyl-cysteine modulates EEG synchronization in schizophrenia patients: a double-blind, randomized, placebo-controlled trial. PLoS One. 2012;7(2):e29341.
   PubMed Web of Science ®Google Scholar
• Breier A, Liffick E, Hummer TA, Vohs JL, Yang Z, Mehdiyoun NF, et al. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Schizophr Res. 2018;199:395–402.
   PubMed Web of Science ®Google Scholar
• Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, et al. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Schizophr Bull. 2018;44(2):317–27.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia–a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008;64(5):361–8.
   PubMed Web of Science ®Google Scholar
• Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, et al. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2013;36(6):185–92.
   PubMed Web of Science ®Google Scholar
• Sepehrmanesh Z, Heidary M, Akasheh N, Akbari H, Heidary M. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2018;82:289–96.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Berk M, Venugopal K, Bush AI, Dodd S, Dean OM. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2015;57:69–75.
   PubMed Web of Science ®Google Scholar
• Rapado-Castro M, Dodd S, Bush AI, Malhi GS, Skvarc DR, On ZX, et al. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Psychol Med. 2017;47(5):866–76.
   PubMed Web of Science ®Google Scholar
• Cadenhead KS, Minichino A, Kelsven S, Addington J, Bearden C, Cannon TD, et al. Metabolic abnormalities and low dietary Omega 3 are associated with symptom severity and worse functioning prior to the onset of psychosis: Findings from the North American Prodrome Longitudinal Studies Consortium. Schizophr Res. 2019;204:96–103.
   PubMed Web of Science ®Google Scholar
• Calder PC. Mechanisms of Action of (n-3) Fatty Acids. J Nutr. 2012;142(3):592S–9S.
   PubMed Web of Science ®Google Scholar
• McNamara RK. Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: Mechanisms and implications for psychopathology. World J Psychiatry. 2015;5(1):15.
   PubMedGoogle Scholar
• Alqarni A, Mitchell TW, McGorry PD, Nelson B, Markulev C, Yuen HP, et al. Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. Schizophr Res. 2020;226:52–60.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2010;67(2):146–54.
   PubMed Web of Science ®Google Scholar
• Amminger GP, Schäfer MR, Schlögelhofer M, Klier CM, McGorry PD. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934.
   PubMed Web of Science ®Google Scholar
• McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, et al. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial. JAMA Psychiatry. 2017;74(1):19–27.
   PubMed Web of Science ®Google Scholar
• Paul Amminger G, et al. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nat Commun. 2015;6:7934.
   PubMed Web of Science ®Google Scholar
• Pawełczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawełczyk A. A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia. J Psychiatr Res. 2016;73:34–44.
   PubMed Web of Science ®Google Scholar
• Li P, Zhang X, Gu L, Zhou J, Deng D. P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib. PLoS One. 2019;14(10):e0223084.
   PubMed Web of Science ®Google Scholar
• Pawełczyk T, Piątkowska-Janko E, Bogorodzki P, Gębski P, Grancow-Grabka M, Trafalska E, et al. Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study. Schizophr Res. 2018;195:168–75.
   PubMed Web of Science ®Google Scholar
• Pawełczyk T, Grancow-Grabka M, Trafalska E, Szemraj J, Żurner N, Pawełczyk A. Telomerase level increase is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: Secondary outcome analysis of the OFFER randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:142–8.
   PubMed Web of Science ®Google Scholar
• Robinson DG, Gallego JA, John M, Hanna LA, Zhang J-P, Birnbaum ML, et al. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone. Schizophr Res. 2019;204:295–303.
   PubMed Web of Science ®Google Scholar
• Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, et al. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia. Schizophr Res. 2014;158(1-3):230–5.
   PubMed Web of Science ®Google Scholar
• Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A Placebo-Controlled Trial of Omega-3 Fatty Acid (Ethyl Eicosapentaenoic Acid) Supplementation for Residual Symptoms and Cognitive Impairment in Schizophrenia. Am J Psychiatry. 2001;158:2071–4.
   PubMed Web of Science ®Google Scholar
• Peet M, et al. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res. 2002;36:7–18.
   PubMed Web of Science ®Google Scholar
• Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. (0920-9964 (Print)).
   Google Scholar
• Emsley R, et al. Randomized, Placebo-Controlled Study of Ethyl-Eicosapentaenoic Acid as Supplemental Treatment in Schizophrenia. Am J Psychiatry. 2002;159:1596–8.
   PubMed Web of Science ®Google Scholar
• Emsley R, Niehaus DJH, Koen L, Oosthuizen PP, Turner HJ, Carey P, et al. The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial. Schizophr Res. 2006;84(1):112–20.
   PubMed Web of Science ®Google Scholar
• Bentsen H, Osnes K, Refsum H, Solberg DK, Bøhmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E + C in schizophrenia. Transl Psychiatry. 2013;3(12):e335.
   PubMedGoogle Scholar
• Jamilian H, Solhi H, Jamilian M. Randomized, Placebo-Controlled Clinical Trial of Omega-3 as Supplemental Treatment in Schizophrenia. Glob J Health Sci. 2014;6(7):103–8.
   PubMedGoogle Scholar
• Qiao Y, Mei Y, Han H, Liu F, Yang XM, Shao Y, et al. Effects of Omega-3 in the treatment of violent schizophrenia patients. Schizophr Res. 2018;195:283–5.
   PubMed Web of Science ®Google Scholar
• Tang W, Wang Y, Xu F, Fan W, Zhang Y, Fan K, et al. Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome. Brain Behav Immun. 2020;88:529–34.
   PubMed Web of Science ®Google Scholar
• Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry. 2007;62(7):739–46.
   PubMed Web of Science ®Google Scholar
• Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006;59(3):230–4.
   PubMed Web of Science ®Google Scholar
• Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005;62(11):1196–204.
   PubMed Web of Science ®Google Scholar
• Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008;63(1):9–12.
   PubMed Web of Science ®Google Scholar
• Greenwood LM, Leung S, Michie PT, Green A, Nathan PJ, Fitzgerald P, et al. The effects of glycine on auditory mismatch negativity in schizophrenia. Schizophr Res. 2018;191:61–9.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Podgórski M, Kałużyńska O, Gawlik-Kotelnicka O, Stefańczyk L, Kotlicka-Antczak M, et al. Supplementation of Antipsychotic Treatment with the Amino Acid Sarcosine Influences Proton Magnetic Resonance Spectroscopy Parameters in Left Frontal White Matter in Patients with Schizophrenia. Nutrients. 2015;7(10):8767–82.
   PubMed Web of Science ®Google Scholar
• Umbricht D, Alberati D, Martin-Facklam M, Borroni E, Youssef EA, Ostland M, et al. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study. JAMA Psychiatry. 2014;71(6):637–46.
   PubMed Web of Science ®Google Scholar
• O’Neill BV, Croft RJ, Mann C, Dang O, Leung S, Galloway MP, et al. High-dose glycine impairs the prepulse inhibition measure of sensorimotor gating in humans. J Psychopharmacol. 2010;25(12):1632–8.
   PubMed Web of Science ®Google Scholar
• Strzelecki D, Podgórski M, Kałużyńska O, Stefańczyk L, Kotlicka-Antczak M, Gmitrowicz A, et al. Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci. 2015;16(10):24475–89.
   PubMed Web of Science ®Google Scholar
• Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry. 2002;159(8):1354–60.
   PubMed Web of Science ®Google Scholar
• Lane H-Y, Huang C-L, Wu P-L, Liu Y-C, Chang Y-C, Lin P-Y, et al. Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia. Biol Psychiatry. 2006;60(6):645–9.
   PubMed Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, et al. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry. 2005;57(6):577–85.
   PubMed Web of Science ®Google Scholar
• Gottlieb JD, Cather C, Shanahan M, Creedon T, Macklin EA, Goff DC. d-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia. Schizophr Res. 2011;131(1-3):69–74.
   PubMed Web of Science ®Google Scholar
• Ota M, Wakabayashi C, Sato N, Hori H, Hattori K, Teraishi T, et al. Effect of l-theanine on glutamatergic function in patients with schizophrenia. Acta Neuropsychiatr. 2015;27(5):291–6.
   PubMed Web of Science ®Google Scholar
• Lane HY, Lin CH, Huang YJ, Liao CH, Chang YC, Tsai GE. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol. 2010;13(4):451–60.
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. (0002-953X (Print)).
   Google Scholar
• Fleischhacker WW, Podhorna J, Gröschl M, Hake S, Zhao Y, Huang S, et al. Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. The Lancet Psychiatry. 2021;8(3):191–201.
   PubMed Web of Science ®Google Scholar
• Wurtman RJ, O'Rourke D, Wurtman JJ. Nutrient imbalances in depressive disorders. Possible brain mechanisms. Ann N Y Acad Sci. 1989;575:75–82.
   PubMed Web of Science ®Google Scholar
• Young SN. Folate and depression–a neglected problem. (1180-4882 (Print)).
   Google Scholar
• Hibbeln JR. Fish consumption and major depression. Lancet. 1998;351(9110):1213.
   PubMed Web of Science ®Google Scholar
• Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006;67(2):362–70.
   PubMed Web of Science ®Google Scholar
• Bell IR, Edman JS, Morrow FD, Marby DW, Mirages S, Perrone G, et al. B complex vitamin patterns in geriatric and young adult inpatients with major depression. J Am Geriatr Soc. 1991;39(3):252–7.
   PubMed Web of Science ®Google Scholar
• Chouinard G, Young SN, Annable L. A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry. 1985;20(5):546–57.
   PubMed Web of Science ®Google Scholar
• McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Järvelin MR, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res. 2004;67(2-3):237–45.
   PubMed Web of Science ®Google Scholar
• Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, et al. Vitamin D Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. EBioMedicine. 2017;26:138–45.
   PubMed Web of Science ®Google Scholar
• Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl). 2005;182(4):494–8.
   PubMed Web of Science ®Google Scholar
• Sanders LLO, de Souza Menezes CE, Chaves Filho AJM, de Almeida Viana G, Fechine FV, Rodrigues de Queiroz MG, et al. α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial. J Clin Psychopharmacol. 2017;37(6):697–701.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry. 2007;68(11):1648–54.
   PubMed Web of Science ®Google Scholar
• Allott K, McGorry PD, Yuen HP, Firth J, Proffitt T-M, Berger G, et al. The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis. Biol Psychiatry. 2019;86(1):35–44.
   PubMed Web of Science ®Google Scholar
• Ghaderi A, Banafshe HR, Mirhosseini N, Moradi M, Karimi MA, Mehrzad F, et al. Clinical and metabolic response to vitamin D plus probiotic in schizophrenia patients. BMC Psychiatry. 2019;19(1):77.
   PubMedGoogle Scholar
• Michael N, Sourgens H, Arolt V, Erfurth A. Severe tardive dyskinesia in affective disorders: treatment with vitamin E and C. Neuropsychobiology. 2002;46(Suppl 1):28–30.
   PubMedGoogle Scholar
• Bentsen H, Landrø NI. Neurocognitive effects of an omega-3 fatty acid and vitamins E + C in schizophrenia: A randomised controlled trial. Prostaglandins Leukot Essent Fatty Acids. 2018;136:57–66.
   PubMed Web of Science ®Google Scholar
• Bošković M, Vovk T, Koprivšek J, Plesničar BK, Grabnar I. Vitamin E and essential polyunsaturated fatty acids supplementation in schizophrenia patients treated with haloperidol. Nutr Neurosci. 2016;19(4):156–61.
   PubMed Web of Science ®Google Scholar
• Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265–9.
   PubMed Web of Science ®Google Scholar
• Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, et al. Randomized Multicenter Investigation of Folate Plus Vitamin B12Supplementation in Schizophrenia. JAMA Psychiatry. 2013;70(5):481.
   PubMed Web of Science ®Google Scholar
• Nechifor M, Vaideanu C, Palamaru I, Borza C, Mindreci I. The influence of some antipsychotics on erythrocyte magnesium and plasma magnesium, calcium, copper and zinc in patients with paranoid schizophrenia. J Am Coll Nutr. 2004;23(5):549s–51s.
   PubMed Web of Science ®Google Scholar
• Jamilian H, Ghaderi A. The Effects of Probiotic and Selenium Co-supplementation on Clinical and Metabolic Scales in Chronic Schizophrenia: a Randomized, Double-blind, Placebo-Controlled Trial. Biol Trace Elem Res. 2021;199(12):4430–8.
   PubMed Web of Science ®Google Scholar
• Vidović B, Dorđević B, Milovanović S, Škrivanj S, Pavlović Z, Stefanović A, et al. Selenium, zinc, and copper plasma levels in patients with schizophrenia: relationship with metabolic risk factors. Biol Trace Elem Res. 2013;156(1-3):22–8.
   PubMed Web of Science ®Google Scholar
• Li Z, Liu Y, Li X, Ju W, Wu G, Yang X, et al. Association of Elements with Schizophrenia and Intervention of Selenium Supplements. Biol Trace Elem Res. 2017;183(1):16–21.
   PubMed Web of Science ®Google Scholar
• Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the Treatment of Tardive Dyskinesia:A Double-Blind, Placebo-Controlled, Crossover Study. Am J Psychiatry. 2001;151:1511–4.
   Google Scholar
• Meramat A, et al. Cognitive impairment, genomic instability and trace elements. J Nutr Health Aging. 2014;19(1):48–57.
   Web of Science ®Google Scholar
• Vaddadi KS, Soosai E, Vaddadi G. Low blood selenium concentrations in schizophrenic patients on clozapine. (0306-5251 (Print)).
   Google Scholar
• Adamowicz K, Kucharska-Mazur J. Dietary Behaviors and Metabolic Syndrome in Schizophrenia Patients. J Clin Med. 2020;9(2):537.
   PubMed Web of Science ®Google Scholar
• Simonelli-Muñoz AJ, Fortea MI, Salorio P, Gallego-Gomez JI, Sánchez-Bautista S, Balanza S. Dietary habits of patients with schizophrenia: A self-reported questionnaire survey. Int J Ment Health Nurs. 2012;21(3):220–8.
   PubMed Web of Science ®Google Scholar
• Jakobsen AS, Speyer H, Nørgaard HCB, Karlsen M, Hjorthøj C, Krogh J, et al. Dietary patterns and physical activity in people with schizophrenia and increased waist circumference. Schizophr Res. 2018;199:109–15.
   PubMed Web of Science ®Google Scholar
• Sorić T, Mavar M, Rumbak I. Metabolic Syndrome and Dietary Habits in Hospitalized Patients with Schizophrenia: A Cross-Sectional Study. Medicina (B Aires). 2021;57(3):255.
   Google Scholar
• Helman DS. Nonmedical Interventions for Schizophrenia. Holist Nurs Pract. 2020;34(2):73–82.
   PubMed Web of Science ®Google Scholar
• Teasdale SB, Ward PB, Rosenbaum S, Watkins A, Curtis J, Kalucy M, et al. A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis. Br J Nutr. 2016;115(11):1987–93.
   PubMed Web of Science ®Google Scholar
• Sorić T, Mavar M, Rumbak I. The Effects of the Dietary Approaches to Stop Hypertension (DASH) Diet on Metabolic Syndrome in Hospitalized Schizophrenic Patients: A Randomized Controlled Trial. Nutrients. 2019;11(12):2950.
   PubMed Web of Science ®Google Scholar
• Kowalski K, Bogudzińska B, Stańczykiewicz B, Piotrowski P, Bielawski T, Samochowiec J, et al. The Deficit Schizophrenia Subtype Is Associated with Low Adherence to the Mediterranean Diet: Findings from a Case–Control Study. J Clin Med. 2022;11(3):568.
   PubMed Web of Science ®Google Scholar
• Kelly DL, Demyanovich HK, Rodriguez KM, Čiháková D, Talor MV, McMahon RP, et al. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. Journal of Psychiatry and Neuroscience. 2019;44(4):269–76.
   PubMed Web of Science ®Google Scholar
• Molteni R, Barnard RJ, Ying Z, et al. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience. 2002;112(4):803–14.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005;62(2):190–8.
   PubMed Web of Science ®Google Scholar
• Graham I, Cooney MT, Bradley D, Dudina A, Reiner Z. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709–20.
   PubMed Web of Science ®Google Scholar
• McCreadie R, Macdonald E, Blacklock C, Tilak-Singh D, Wiles D, Halliday J, et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. Br Med J. 1998;317(7161):784–5.
   PubMedGoogle Scholar
• Peet M. International variations in the outcome of schizophrenia and the prevalence of depressionof schizophrenia and the prevalence of depression in relation to national dietary practices:in relation to national dietary practices: an ecological analysisan ecological analysis. British J ournal of Psychiatry. 2004;184:404–8.
   PubMed Web of Science ®Google Scholar
• Curtis J, Watkins A, Rosenbaum S, Teasdale S, Kalucy M, Samaras K, et al. Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis. Early Interv Psychiatry. 2016;10(3):267–76.
   PubMed Web of Science ®Google Scholar
• Attux C, Martini LC, Elkis H, Tamai S, Freirias A, Camargo M, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. BMC Psychiatry. 2013;13(60):60.
   PubMedGoogle Scholar
• Eklund M, Tjörnstrand C, Sandlund M, Argentzell E. Effectiveness of Balancing Everyday Life (BEL) versus standard occupational therapy for activity engagement and functioning among people with mental illness – a cluster RCT study. BMC Psychiatry. 2017;17(1):363.
   PubMedGoogle Scholar
• Baker AL, Richmond R, Kay-Lambkin FJ, Filia SL, Castle D, Williams JM, et al. Randomised controlled trial of a healthy lifestyle intervention among smokers with psychotic disorders: Outcomes to 36 months. Aust N Z J Psychiatry. 2017;52(3):239–52.
   PubMed Web of Science ®Google Scholar
• Holt RIG, Gossage-Worrall R, Hind D, Bradburn MJ, McCrone P, Morris T, et al. Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial. Br J Psychiatry. 2018;214(2):63–73.
   PubMed Web of Science ®Google Scholar
• Ito H, Kumagai T, Iwama T. Evaluation of an educational wellness program by sex differences in community-dwelling Japanese patients with schizophrenia. Arch Psychiatr Nurs. 2021;35(5):450–6.
   PubMed Web of Science ®Google Scholar
• Masa-Font R, Fernández-San-Martín MI, Martín López LM, Alba Muñoz AM, Oller Canet S, Martín Royo J, et al. The effectiveness of a program of physical activity and diet to modify cardiovascular risk factors in patients with severe mental illness after 3-month follow-up: CAPiCOR randomized clinical trial. Eur Psychiatry. 2015;30(8):1028–36.
   PubMed Web of Science ®Google Scholar
• Stiekema APM, Looijmans A, van der Meer L, Bruggeman R, Schoevers RA, Corpeleijn E, et al. Effects of a lifestyle intervention on psychosocial well-being of severe mentally ill residential patients: ELIPS, a cluster randomized controlled pragmatic trial. Schizophr Res. 2018;199:407–13.
   PubMed Web of Science ®Google Scholar